Gilead buys out cash-hun­gry part­ner Jounce's an­ti­body for $67M

Gilead Sci­ences has bought out Jounce Ther­a­peu­tics’ an­ti-CCR8 an­ti­body for $67 mil­lion, tak­ing over full R&D and com­mer­cial rights to the ex­per­i­men­tal can­cer im­munother­a­py drug.

The deal will give Jounce enough cash to keep op­er­at­ing in­to the third quar­ter of 2024, said Cowen an­a­lyst Boris Peak­er. But it means the Cam­bridge, MA-based com­pa­ny will for­go as much as $645 mil­lion in mile­stone pay­ments, the com­pa­nies said, plus roy­al­ties from any sales that the com­pa­nies had agreed to when Gilead li­censed the drug from Jounce in Au­gust 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER